MoneyWorks4Me

Jenburkt Pharmaceuticals planning to launch Favipiravir-200 mg tablets

21 Jul 2020 Evaluate

Jenburkt Pharmaceuticals has planned to launch Favipiravir-200 mg tablets, recommended for the treatment of mild to moderate COVID-19 patients.

Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.

Jenburkt Pharma Share Price

1043.55 -18.20 (-1.71%)
17-Aug-2026 11:57 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1906.00
Dr. Reddys Labs. 1192.45
Cipla 1428.90
Lupin 2222.80
Zydus Lifesciences 1152.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: